Literature DB >> 33341519

Predicting 1-, 3- and 5-year outcomes in patients with coronary artery disease: A comparison of available risk assessment scores.

Monika Zdanyte1, Robin W Wrazidlo1, Sarah Kaltenbach2, Patrick Groga-Bada1, Meinrad Gawaz1, Tobias Geisler1, Dominik Rath3.   

Abstract

BACKGROUND AND AIMS: Thromboischemic and bleeding events are rare but life-threatening complications after percutaneous coronary intervention (PCI). Various risk assessment models have been established to predict short- and long-term adverse events in patients with chronic and acute coronary syndromes (CCS, ACS). The aim of the present study was to compare available risk assessment systems based on their performance in identifying high-risk patients with symptomatic coronary artery disease (CAD).
METHODS: We enrolled 1565 consecutive patients with symptomatic CAD (n = 821 CCS, n = 744 ACS). CALIBER, DAPT, GRACE 2.0, PARIS-CTE, PARIS-MB, PRECISE-DAPT and PREDICT-STABLE scores were calculated in appropriate patient subgroups. All patients were followed-up for 1, 3 and 5 years for all-cause death (ACD), myocardial infarction (MI), ischemic stroke (IS) and bleeding. The primary combined ischemic endpoint (CE) consisted of ACD, MI and/or IS. Secondary endpoints were defined as single occurrence of either ACD, MI, IS, or bleeding.
RESULTS: GRACE 2.0 score showed good discrimination performance (AUC>0.7) for CE in a 3- and 5-year follow-up. CALIBER, GRACE 2.0 and PARIS-CTE showed best performance (AUC>0.7) in predicting ACD throughout the follow-up, whereas IS was best predicted by PARIS-CTE and CALIBER scores. None of the scores performed well (AUC>0.7) in predicting MI or bleeding.
CONCLUSIONS: In a consecutive German CAD cohort, CALIBER, GRACE 2.0 and PARIS-CTE scores performed best in predicting CE, ACD and/or IS whereas none of the selected scores could predict MI and bleeding efficiently.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Haemorrhage; Ischemia; Prognosis; Risk assessment

Mesh:

Year:  2020        PMID: 33341519     DOI: 10.1016/j.atherosclerosis.2020.12.007

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  3 in total

1.  Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals.

Authors:  Hiroyoshi Yokoi; Eisei Oda; Kazuki Kaneko; Kenta Matsubayashi
Journal:  Cardiovasc Interv Ther       Date:  2022-02-09

2.  Comparison of GRACE and TIMI risk scores in the prediction of in-hospital and long-term outcomes among East Asian non-ST-elevation myocardial infarction patients.

Authors:  Lu Yanqiao; Lan Shen; Miao Yutong; Shen Linghong; He Ben
Journal:  BMC Cardiovasc Disord       Date:  2022-01-07       Impact factor: 2.298

3.  Development and validation of a novel risk score to predict 5-year mortality in patients with acute myocardial infarction in China: a retrospective study.

Authors:  Yan Tang; Yuanyuan Bai; Yuanyuan Chen; Xuejing Sun; Yunmin Shi; Tian He; Mengqing Jiang; Yujie Wang; Mingxing Wu; Zhiliu Peng; Suzhen Liu; Weihong Jiang; Yao Lu; Hong Yuan; Jingjing Cai
Journal:  PeerJ       Date:  2022-01-04       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.